Pregabalin Capsule
Product Images NDC 50090-5071

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-5071). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905071)

Label for Pregabalin 75 mg oral capsules from A-S Medication Solutions. The label shows dosage strength, storage instructions (store at 77 degrees F), quantity of 90 capsules per container, and includes NDC 50090-5071. The label also displays a QR code and lot information.*

FDA Label Image

Equation (Pregabain Gault Equation)

A mathematical equation calculating creatinine clearance (CLCr), showing variables of age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor of 0.85 for female patients.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing placebo and pregabalin doses of 25 mg, 100 mg, and 200 mg three times a day. The graph illustrates treatment effectiveness with pregabalin doses and placebo over the improvement range.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier curve comparing percent improvement in pain from baseline versus percent of patients improved over different thresholds for Pregabalin 100 mg three times a day (dashed line) and placebo (dotted line). The y-axis shows the percent of patients improved, and the x-axis shows percent improvement in pain from baseline, marked at increments from >0 to 100.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo, illustrating their relative efficacy in pain improvement over different percentages.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A cumulative distribution plot showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The chart compares three groups: Pregabalin 200 mg three times a day (solid line), Pregabalin 100 mg three times a day (dashed line), and placebo (dotted line). The plot illustrates patient response rates to different doses of Pregabalin versus placebo.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A cumulative response curve chart showing percent of patients improved on the y-axis and percent improvement in pain from baseline on the x-axis. The chart compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line).*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

Bar graph displaying responder rates (%) from two studies, Study E1 and Study E3. Study E1 shows increasing responder rates with Pregabalin doses from 50 mg to 600 mg per day (BID), compared to placebo. Study E3 compares placebo to 600 mg per day given BID and TID, with higher responder rates for the drug. The x-axis represents treatment groups, and the y-axis shows responder rates in percent.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A chart depicting seizure reduction as median percent change from baseline versus dose in mg/day. The chart compares four Stukly dosing regimens labeled E1BID, E2BID, E3BID, and E3TID, with p-values indicating statistical significance for the observed reductions. Doses range from 0 (placebo) to 600 mg/day, showing increased seizure reduction with higher doses across the regimens.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line graph depicting percent improvement in pain from baseline (x-axis, 0 to 100%) versus percent of patients improved (y-axis, 0 to 100%). Four curves illustrate data for Pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and placebo, showing how patient response varies by dose.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart depicting the estimated percentage of subjects without LTR over 180 days, comparing Pregabalin treatment (solid line) to placebo (dashed line). The y-axis shows the estimated percentage without LTR from 0% to 100%, while the x-axis represents time in days from 0 to 180.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph depicting the percent of subjects improved from baseline to week 12 using a BOCF (Baseline Observation Carried Forward) method. The x-axis shows the percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved, ranging from 0 to 100. Two lines are plotted: a solid line for Pregabalin and a dotted line for Placebo, illustrating comparative improvement rates over different percentages.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percent of subjects improved over baseline to week 16 by percent improvement, showing two curves: one for Pregabalin and one for Placebo. The vertical axis represents percent of subjects improved from 0 to 100, and the horizontal axis represents percent improvement from baseline to week 16. The Pregabalin group shows consistently higher percentages of improvement compared to Placebo across the range.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of pregabalin, showing its molecular arrangement including an amino group, alkyl chains, and a carboxyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.